Loading...

Orion Oyj

OTCPK:ORIN.F
Snowflake Description

Flawless balance sheet with limited growth.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
ORIN.F
OTCPK
€4B
Market Cap
  1. Home
  2. US
  3. Pharmaceuticals & Biotech
Company description

Orion Oyj engages in the development and manufacture of pharmaceuticals, active pharmaceutical ingredients (APIs), and diagnostic tests worldwide. The last earnings update was 52 days ago. More info.


Add to Portfolio Compare Print
ORIN.F Share Price and Events
7 Day Returns
0%
OTCPK:ORIN.F
-0.5%
US Pharmaceuticals
0.5%
US Market
1 Year Returns
-
OTCPK:ORIN.F
6%
US Pharmaceuticals
0.8%
US Market
ORIN.F Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Orion Oyj (ORIN.F) 0% -11% - - - -
US Pharmaceuticals -0.5% 0.9% -2.7% 6% 9.1% 14%
US Market 0.5% 0.2% 1.1% 0.8% 37.4% 37.5%
1 Year Return vs Industry and Market
  • No trading data on ORIN.F.
  • No trading data on ORIN.F.
Price Volatility
ORIN.F
Industry
5yr Volatility vs Market

Value

 Is Orion Oyj undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Orion Oyj to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Orion Oyj.

OTCPK:ORIN.F Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 7 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 7.9%
Perpetual Growth Rate 10-Year US Government Bond Rate 2.7%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for OTCPK:ORIN.F
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year US Govt Bond Rate 2.7%
Equity Risk Premium S&P Global 6.5%
Pharmaceuticals Unlevered Beta Simply Wall St/ S&P Global 0.64
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.64 (1 + (1- 20%) (3.59%))
0.771
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
0.8
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 2.73% + (0.8 * 6.51%)
7.94%

Discounted Cash Flow Calculation for OTCPK:ORIN.F using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Orion Oyj is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

OTCPK:ORIN.F DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (EUR, Millions) Source Present Value
Discounted (@ 7.94%)
2019 192.50 Analyst x5 178.34
2020 200.46 Analyst x5 172.06
2021 192.26 Analyst x5 152.89
2022 205.27 Analyst x3 151.22
2023 217.07 Analyst x3 148.16
2024 223.53 Est @ 2.98% 141.35
2025 230.02 Est @ 2.9% 134.76
2026 236.58 Est @ 2.85% 128.41
2027 243.24 Est @ 2.82% 122.31
2028 250.03 Est @ 2.79% 116.48
Present value of next 10 years cash flows €1,445.98
OTCPK:ORIN.F DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= €250.03 × (1 + 2.73%) ÷ (7.94% – 2.73%)
€4,931.96
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= €4,931.96 ÷ (1 + 7.94%)10
€2,297.61
OTCPK:ORIN.F Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= €1,445.98 + €2,297.61
€3,743.59
Equity Value per Share
(EUR)
= Total value / Shares Outstanding
= €3,743.59 / 140.49
€26.65
OTCPK:ORIN.F Discount to Share Price
Calculation Result
Value per share (USD) From above. $28.15
Current discount Discount to share price of $33.20
= -1 x ($33.20 - $28.15) / $28.15
-18%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

  • The current share price of Orion Oyj is above its future cash flow value.
Often investors are willing to pay a premium for a company that has a high dividend or the potential for future growth.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Orion Oyj's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Orion Oyj's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
OTCPK:ORIN.F PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-03-31) in EUR €1.33
HLSE:ORNBV Share Price ** HLSE (2019-05-23) in EUR €31.43
United States of America Pharmaceuticals Industry PE Ratio Median Figure of 29 Publicly-Listed Pharmaceuticals Companies 17.22x
United States of America Market PE Ratio Median Figure of 3,091 Publicly-Listed Companies 17.68x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Orion Oyj.

OTCPK:ORIN.F PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= HLSE:ORNBV Share Price ÷ EPS (both in EUR)

= 31.43 ÷ 1.33

23.71x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Orion Oyj is overvalued based on earnings compared to the US Pharmaceuticals industry average.
  • Orion Oyj is overvalued based on earnings compared to the United States of America market.
Price based on expected Growth
Does Orion Oyj's expected growth come at a high price?
Raw Data
OTCPK:ORIN.F PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 23.71x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 7 Analysts
6.6%per year
United States of America Pharmaceuticals Industry PEG Ratio Median Figure of 21 Publicly-Listed Pharmaceuticals Companies 1.55x
United States of America Market PEG Ratio Median Figure of 2,125 Publicly-Listed Companies 1.52x

*Line of best fit is calculated by linear regression .

OTCPK:ORIN.F PEG (Price to Earnings to Growth) Ratio Calculation
Calculation Outcome
PEG Ratio

= PE Ratio ÷ Net Income Annual Growth Rate

= 23.71x ÷ 6.6%

3.6x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Orion Oyj is poor value based on expected growth next year.
Price based on value of assets
What value do investors place on Orion Oyj's assets?
Raw Data
OTCPK:ORIN.F PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-03-31) in EUR €4.31
HLSE:ORNBV Share Price * HLSE (2019-05-23) in EUR €31.43
United States of America Pharmaceuticals Industry PB Ratio Median Figure of 183 Publicly-Listed Pharmaceuticals Companies 3.16x
United States of America Market PB Ratio Median Figure of 5,244 Publicly-Listed Companies 1.79x
OTCPK:ORIN.F PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= HLSE:ORNBV Share Price ÷ Book Value per Share (both in EUR)

= 31.43 ÷ 4.31

7.29x

* Primary Listing of Orion Oyj.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Orion Oyj is overvalued based on assets compared to the US Pharmaceuticals industry average.
X
Value checks
We assess Orion Oyj's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Pharmaceuticals industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Pharmaceuticals industry average (and greater than 0)? (1 check)
  5. Orion Oyj has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Orion Oyj expected to perform in the next 1 to 3 years based on estimates from 7 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
6.6%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Orion Oyj expected to grow at an attractive rate?
  • Orion Oyj's earnings growth is expected to exceed the low risk savings rate of 2.7%.
Growth vs Market Checks
  • Orion Oyj's earnings growth is positive but not above the United States of America market average.
  • Orion Oyj's revenue growth is positive but not above the United States of America market average.
Annual Growth Rates Comparison
Raw Data
OTCPK:ORIN.F Future Growth Rates Data Sources
Data Point Source Value (per year)
OTCPK:ORIN.F Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 7 Analysts 6.6%
OTCPK:ORIN.F Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 7 Analysts 3.3%
United States of America Pharmaceuticals Industry Earnings Growth Rate Market Cap Weighted Average 14.7%
United States of America Pharmaceuticals Industry Revenue Growth Rate Market Cap Weighted Average 5.3%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 13.9%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.3%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
OTCPK:ORIN.F Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 7 Analyst Estimates (S&P Global) See Below
All numbers in EUR Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
OTCPK:ORIN.F Future Estimates Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 1,146 293 257 3
2022-12-31 1,116 276 237 4
2021-12-31 1,044 243 203 5
2020-12-31 1,023 249 196 7
2019-12-31 1,013 237 196 7
OTCPK:ORIN.F Past Financials Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income *
2019-03-31 971 226 187
2018-12-31 978 230 197
2018-09-30 1,032 213 205
2018-06-30 1,052 241 213
2018-03-31 1,015 234 206
2017-12-31 1,034 228 219
2017-09-30 1,048 249 212
2017-06-30 1,065 241 242
2017-03-31 1,077 259 253
2016-12-31 1,074 249 249
2016-09-30 1,055 248 241
2016-06-30 1,036 240 214

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Orion Oyj's earnings are expected to grow by 6.6% yearly, however this is not considered high growth (20% yearly).
  • Orion Oyj's revenue is expected to grow by 3.3% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
OTCPK:ORIN.F Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 7 Analyst Estimates (S&P Global) See Below

All data from Orion Oyj Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

OTCPK:ORIN.F Future Estimates Data
Date (Data in EUR Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 1.83 1.87 1.78 2.00
2022-12-31 1.68 1.71 1.64 3.00
2021-12-31 1.44 1.59 1.36 5.00
2020-12-31 1.36 1.52 1.19 7.00
2019-12-31 1.36 1.41 1.12 7.00
OTCPK:ORIN.F Past Financials Data
Date (Data in EUR Millions) EPS *
2019-03-31 1.33
2018-12-31 1.40
2018-09-30 1.46
2018-06-30 1.52
2018-03-31 1.46
2017-12-31 1.56
2017-09-30 1.51
2017-06-30 1.72
2017-03-31 1.80
2016-12-31 1.77
2016-09-30 1.71
2016-06-30 1.52

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Orion Oyj is expected to efficiently use shareholders’ funds in the future (Return on Equity greater than 20%).
X
Future performance checks
We assess Orion Oyj's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Orion Oyj has a total score of 2/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Orion Oyj performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Orion Oyj's growth in the last year to its industry (Pharmaceuticals).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Orion Oyj's year on year earnings growth rate was negative over the past 5 years and the most recent earnings are below average.
  • Orion Oyj's 1-year earnings growth is negative, it can't be compared to the 5-year average.
  • Orion Oyj's 1-year earnings growth is negative, it can't be compared to the US Pharmaceuticals industry average.
Earnings and Revenue History
Orion Oyj's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Orion Oyj Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

OTCPK:ORIN.F Past Revenue, Cash Flow and Net Income Data
Date (Data in EUR Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-03-31 971.30 186.50 244.30 104.70
2018-12-31 977.50 197.40 238.00 104.00
2018-09-30 1,032.10 205.10 247.00 108.70
2018-06-30 1,051.80 213.40 246.10 107.50
2018-03-31 1,015.30 205.90 237.60 100.50
2017-12-31 1,033.60 219.00 237.00 99.10
2017-09-30 1,047.50 212.10 243.80 110.50
2017-06-30 1,064.50 242.00 246.10 114.10
2017-03-31 1,077.00 252.50 245.00 117.60
2016-12-31 1,073.50 249.00 243.10 118.20
2016-09-30 1,055.20 240.90 235.20 111.90
2016-06-30 1,035.80 213.80 233.10 108.30
2016-03-31 1,017.70 205.80 231.60 107.80
2015-12-31 1,015.60 208.20 235.30 108.10
2015-09-30 1,009.30 209.70 237.20 104.80
2015-06-30 1,008.50 214.00 236.50 102.50
2015-03-31 1,030.20 224.40 237.20 105.10
2014-12-31 1,015.30 211.30 234.90 106.20
2014-09-30 1,032.60 226.10 240.30 107.60
2014-06-30 1,031.20 225.50 242.40 107.90
2014-03-31 1,002.50 203.20 244.60 103.60
2013-12-31 1,006.90 206.20 248.00 101.90
2013-09-30 988.70 192.90 244.50 104.10
2013-06-30 997.60 200.50 249.30 109.20
2013-03-31 982.40 203.40 246.60 107.30
2012-12-31 980.40 206.90 248.00 105.80
2012-09-30 962.10 209.70 240.30 99.30
2012-06-30 926.90 200.90 240.10 92.30

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • Orion Oyj has efficiently used shareholders’ funds last year (Return on Equity greater than 20%).
  • Orion Oyj used its assets more efficiently than the US Pharmaceuticals industry average last year based on Return on Assets.
  • Orion Oyj's use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).
X
Past performance checks
We assess Orion Oyj's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Pharmaceuticals industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Orion Oyj has a total score of 2/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Orion Oyj's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Orion Oyj's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Orion Oyj is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Orion Oyj's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Orion Oyj's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is covered by short term assets, assets are 4.9x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Orion Oyj Company Filings, last reported 2 months ago.

OTCPK:ORIN.F Past Debt and Equity Data
Date (Data in EUR Millions) Total Equity Total Debt Cash & Short Term Investments
2019-03-31 606.80 158.30 341.20
2018-12-31 773.10 151.50 283.70
2018-09-30 736.80 151.50 254.80
2018-06-30 702.40 151.40 205.30
2018-03-31 518.50 190.10 76.80
2017-12-31 679.70 151.40 164.10
2017-09-30 594.60 151.40 133.10
2017-06-30 550.30 151.40 67.70
2017-03-31 494.80 152.40 92.10
2016-12-31 641.40 152.50 231.90
2016-09-30 588.90 173.30 198.20
2016-06-30 523.00 186.70 119.70
2016-03-31 475.10 185.90 282.50
2015-12-31 594.90 187.80 245.20
2015-09-30 505.10 219.70 220.20
2015-06-30 461.00 229.50 169.40
2015-03-31 401.80 230.70 312.20
2014-12-31 514.90 234.50 258.50
2014-09-30 515.50 242.90 213.60
2014-06-30 464.10 252.80 164.90
2014-03-31 392.00 254.00 254.30
2013-12-31 513.90 257.80 214.70
2013-09-30 477.40 270.90 172.80
2013-06-30 427.40 278.20 138.60
2013-03-31 382.30 175.10 192.70
2012-12-31 509.50 136.70 145.20
2012-09-30 468.70 149.90 114.30
2012-06-30 410.80 157.50 62.10
  • Orion Oyj's level of debt (26.1%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has been reduced over the past 5 years (64.7% vs 26.1% today).
  • Debt is well covered by operating cash flow (142.5%, greater than 20% of total debt).
  • Interest payments on debt are well covered by earnings (EBIT is 59.6x coverage).
X
Financial health checks
We assess Orion Oyj's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Orion Oyj has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Orion Oyj's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
4.77%
Current annual income from Orion Oyj dividends. Estimated to be 4.75% next year.
If you bought $2,000 of Orion Oyj shares you are expected to receive $95 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Orion Oyj's pays a higher dividend yield than the bottom 25% of dividend payers in United States of America (1.47%).
  • Orion Oyj's dividend is above the markets top 25% of dividend payers in United States of America (3.71%).
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
OTCPK:ORIN.F Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 7 Analyst Estimates (S&P Global) See Below
United States of America Pharmaceuticals Industry Average Dividend Yield Market Cap Weighted Average of 10 Stocks 2.7%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 2011 Stocks 2.5%
United States of America Minimum Threshold Dividend Yield 10th Percentile 0.8%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.5%
United States of America Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

OTCPK:ORIN.F Future Dividends Estimate Data
Date (Data in €) Dividend per Share (annual) Avg. No. Analysts
2023-12-31 1.56 2.00
2022-12-31 1.52 2.00
2021-12-31 1.50 5.00
2020-12-31 1.48 7.00
2019-12-31 1.47 6.00
OTCPK:ORIN.F Past Annualized Dividends Data
Date (Data in €) Dividend per share (annual) Avg. Yield (%)
2019-03-04 1.500 4.760
2019-02-06 1.500 4.896
2018-02-07 1.450 5.180
2017-03-22 1.350 3.305
2016-03-22 1.300 3.535
2015-03-02 1.300 4.132
2015-02-04 1.300 4.570
2014-02-04 1.250 4.814
2013-02-05 1.300 6.626
2012-07-31 1.420 7.616
2012-02-07 1.420 9.312
2011-02-09 1.260 7.955
2010-02-09 1.000 6.523

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Whilst dividend payments have been stable, Orion Oyj has been paying a dividend for less than 10 years.
  • Dividend payments have increased, but Orion Oyj only paid a dividend in the past 9 years.
Current Payout to shareholders
What portion of Orion Oyj's earnings are paid to the shareholders as a dividend.
  • Dividends paid are not well covered by earnings (0.9x coverage).
Future Payout to shareholders
  • Dividends after 3 years are not well covered by earnings (1x coverage).
X
Income/ dividend checks
We assess Orion Oyj's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Orion Oyj afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Orion Oyj has a total score of 2/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Orion Oyj's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Timo Lappalainen
COMPENSATION €1,346,660
AGE 56
TENURE AS CEO 11.4 years
CEO Bio

Mr. Timo Lappalainen, M.Sc. (Ind. Eng.), has been the Chief Executive Officer and President of Orion Oyj (Formerly, Orion Corporation) since January 2008. Mr. Lappalainen has been the Chairman of the Executive Management Board at Orion Oyj since January 01, 2008. He served as a Member of Management Board, Senior Vice President and Deputy President of Human Pharmaceuticals of Orion Pharma at Orion Oyj. He joined Orion in 1999 as Senior Vice President of Business Development of Orion Pharma and served as its Executive Vice President since 2003. Mr. Lappalainen served as Senior Vice President of Proprietary Products Animal Health and Business Support of Orion Oyj. He started his career as a Consultant with Arthur Andersen in Chicago in 1987. From 1989 to 1993, he served as a Head of Business Development of Finvest Ltd. From 1994 to 1999, he served as the Head of several functions with Leiras Oy (subsidiary of Schering AG). He serves as the Chairman of Orion Diagnostica Oy. He served as the Chairman of Finnzymes Oy since 2007 and served as its Director. He has been a Director at Kemira Oyj since March 24, 2014. He served as a Director of Vaisala Oyj since February 14, 2011. Mr. Lappalainen holds a Master of Science degree in Engineering.

CEO Compensation
  • Timo's compensation has been consistent with company performance over the past year, both up more than 20%.
  • Timo's remuneration is lower than average for companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the Orion Oyj management team in years:

10.8
Average Tenure
54
Average Age
  • The average tenure for the Orion Oyj management team is over 5 years, this suggests they are a seasoned and experienced team.
Management Team

Timo Lappalainen

TITLE
CEO, President & Chairman of the Executive Management Board
COMPENSATION
€1M
AGE
56
TENURE
11.4 yrs

Jari Karlson

TITLE
CFO, Senior VP of Animal Health & Member of the Executive Management Board
AGE
57
TENURE
16.8 yrs

Olli Huotari

TITLE
Senior VP of Corporate Functions
AGE
52

Markku Huhta-Koivisto

TITLE
Senior VP of Growth Projects & Member of Executive Management Board
AGE
62

Satu Ahomäki

TITLE
Senior VP of Commercial Operations and Member of the Executive Management Board
AGE
52
TENURE
11.4 yrs

Liisa Hurme

TITLE
Senior VP of Supply Chain & Member of the Executive Management Board
AGE
51

Virve Laitinen

TITLE
Senior VP of Specialty Products & Member of Executive Management Board
AGE
46
TENURE
7.4 yrs

Marko Torppala

TITLE
Employee Representative Executive Management Board

Christer Nordstedt

TITLE
Senior VP of Research & Development and Member of Executive Management Board
AGE
56
TENURE
2.3 yrs

Terhi Ormio

TITLE
Vice President of Communications
TENURE
10.2 yrs
Board of Directors Tenure

Average tenure and age of the Orion Oyj board of directors in years:

2.3
Average Tenure
55
Average Age
  • The average tenure for the Orion Oyj board of directors is less than 3 years, this suggests a new board.
Board of Directors

Heikki Westerlund

TITLE
Chairman
COMPENSATION
€118K
AGE
52
TENURE
2.3 yrs

Timo Maasilta

TITLE
Vice Chairman
COMPENSATION
€80K
AGE
64
TENURE
3.3 yrs

Mikael Silvennoinen

TITLE
Director
COMPENSATION
€63K
AGE
62
TENURE
5.3 yrs

Eija Ronkainen

TITLE
Director
COMPENSATION
€57K
AGE
52
TENURE
3.3 yrs

Ari Lehtoranta

TITLE
Director
COMPENSATION
€57K
AGE
55
TENURE
2.3 yrs

Hilpi Rautelin

TITLE
Director
COMPENSATION
€57K
AGE
57
TENURE
2.3 yrs

Pia Kalsta

TITLE
Director
AGE
48
TENURE
0.3 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
X
Management checks
We assess Orion Oyj's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Orion Oyj has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Orion Oyj engages in the development and manufacture of pharmaceuticals, active pharmaceutical ingredients (APIs), and diagnostic tests worldwide. The company operates in two segments, Pharmaceuticals and Diagnostics. The Pharmaceuticals segment develops, manufactures, and markets pharmaceuticals and APIs. This segment provides proprietary drugs in the areas of central nervous system, oncology and critical care, and pulmonary care; generic prescription drugs, as well as self-care products, such as non-prescription medicines, basic ointments, and vitamins; proprietary and generic veterinary drugs; and APIs for generic and proprietary drugs, as well as offers contract manufacturing services for APIs. This segment also markets and sells veterinary drugs manufactured by other international companies. The Diagnostics segment develops, manufactures, and markets in vitro diagnostic test systems and tests for diagnosing diseases and monitoring treatment efficacy. Orion Oyj has a strategic alliance with Novan, Inc. to manufacture topical nitric oxide-releasing product candidates; and research collaboration with Fifth Corner Inc. to seek solutions to improve the quality of life of prostate cancer patients. The company was founded in 1917 and is headquartered in Espoo, Finland.

Details
Name: Orion Oyj
ORIN.F
Exchange: OTCPK
Founded: 1917
€4,949,938,288
140,492,429
Website: http://www.orion.fi
Address: Orion Oyj
Orionintie 1A,
Espoo,
Uusimaa, 02200,
Finland
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
HLSE ORNBV Class B Shares OMX Nordic Exchange Helsinki FI EUR 03. Jul 2006
OTCPK ORIN.F Class B Shares Pink Sheets LLC US USD 03. Jul 2006
DB OFK Class B Shares Deutsche Boerse AG DE EUR 03. Jul 2006
LSE 0M2O Class B Shares London Stock Exchange GB EUR 03. Jul 2006
BATS-CHIXE ORNBVH Class B Shares BATS 'Chi-X Europe' GB EUR 03. Jul 2006
OTCPK ORIN.Y ADR Pink Sheets LLC US USD 05. Apr 2010
HLSE ORNAV Class A Shares OMX Nordic Exchange Helsinki FI EUR 03. Jul 2006
LSE 0M2N Class A Shares London Stock Exchange GB EUR 03. Jul 2006
BATS-CHIXE ORNAVH Class A Shares BATS 'Chi-X Europe' GB EUR 03. Jul 2006
Number of employees
Current staff
Staff numbers
3,184
Orion Oyj employees.
Industry
Pharmaceuticals
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/06/16 00:17
End of day share price update: 2019/05/23 00:00
Last estimates confirmation: 2019/05/22
Last earnings filing: 2019/04/25
Last earnings reported: 2019/03/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.